Opioid Use Disorder Market Worth $4.5 Billion by 2026 | CAGR: 10.1%: Grand View Research, Inc.

SAN FRANCISCO, July 30, 2019 /PRNewswire/ -- The global opioid use disorder market size is expected to reach USD 4.5 billion by 2026, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 10.1% over the forecast period. Rising opioid epidemic and growing government initiatives to combat the crisis are likely to propel market growth. In addition, growing commercialization of novel products is further anticipated to drive growth. In 2018, about 2.9 million people aged 15 or above were suffering from this disorder in the U.S. In 2016, according to the National Survey on Drug Use and Health (NSDUH), in the U.S., around 11.5 million people had abused prescription opioids in the earlier year and more than 2 million were addicted to prescribed drugs.

Key suggestions from the report:

• Buprenorphine was the largest revenue generating segment in 2018. Its sublingual tablets and branded drug Suboxone are the most widely prescribed drug for OUD
• Suboxone is the highest prescribed drug in the OUD market, mostly due to its excellent clinical profile
• Sublocade, a buprenorphine product, is estimated to be the largest and fastest growing product over the forecast period, as it is the first long-acting buprenorphine and the first once-monthly product
• North America generated the highest revenue in 2018, followed by Europe
• Some of the major players in the opioid use disorder market include are Indivior, Alkermes, Titan Pharmaceuticals, Hikma Pharmaceuticals, Teva Pharmaceuticals, MediciNova, Orexo, Camurus, and Omeros
• The key players are adopting strategies such as mergers and acquisitions, product development, product extension, and regional expansion to increase their market share
• In 2018, Orexo AB announced that it obtained the rights to commercialize Zubsolv in all the territories outside the U.S. from its current partner Mundipharma

Read 185 page research report with TOC on "Opioid Use Disorder Market Size, Share & Trends Analysis Report By Drug (Buprenorphine, Methadone, Naltrexone), Competitive Landscape, And Segment Forecasts, 2019 - 2026" at: https://www.grandviewresearch.com/industry-analysis/opioid-use-disorder-market

According to the CDC, around 130 Americans die every day due to the opioid overdose and the U.S. government has designated this as a public health emergency.For patients wanting to overcome their addiction, adherence to a Medication-assisted Treatment (MAT) can reduce the withdrawal symptoms and cut the risk of death by half. Three U.S. FDA-approved MAT options are buprenorphine, methadone, and naltrexone. They are available in numerous dosages and formulations, with daily oral buprenorphine as the standard of care.

To combat the opioid crisis, several measures have been undertaken in recent years. For instance, in 2016, CDC clinical practice guidelines for prescribing these drugs for chronic pain were issued and new American Society of Addiction Medicine (ASAM) National Practice Guidelines was adopted in 2015 to improve standard of care. Furthermore, in 2016, the U.S. FDA announced plans to overhaul its regulations for abuse-deterrent opioids, enhance safety labeling, and re-examine the risk-benefit paradigm of their use.

Grand View Research has segmented the opioid use disorder market on the basis of drug and region:

• Opioid Use Disorder Drug Outlook (Revenue, USD Million, 2015 - 2026)
• Buprenorphine
• Bunavail
• Sublocade
• Suboxone
• Zubsolv
• Others
• Methadone
• Naltrexone
• Opioid Use Disorder Regional Outlook (Revenue, USD Million, 2015 - 2026)
• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Italy
• Spain
• Asia Pacific
• Australia
• China
• Latin America and Middle East & Africa
• Brazil
• South Africa

Find more research reports on Pharmaceuticals Industry, by Grand View Research:

• Combination Drugs Diagnostic Market – Global combination drugs diagnostic market is expected to witness exponential growth over the coming seven years due to greater efficiency attached to combination diagnosis and accelerated approval of drugs by the regulating authority.
• Biopreservation Market – Global bio-preservation market is expected to witness a lucrative growth rate over the forecast period owing to expansion of both bio-preservation media market and the bio-preservation equipment market.
• Anti-Cancer Drug Market – Drug approval from regional regulatory bodies is an important growth factor and therefore support from the regional government bodies and non-profit organization are expected to drive global anti-cancer drug market demand over the forecast period.

Gain access to Grand View Compass, our BI enabled intuitive market research database of 10,000+ reports

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.

Contact:

Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc.
Phone: +1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com
Web: https://www.grandviewresearch.com
Follow Us: LinkedIn | Twitter

Logo: https://mma.prnewswire.com/media/661327/Grand_View_Research_Logo.jpg